Inclusion Criteria:  Patients treated with calcium dobesilate (1000-2000mg/day), at any time on treatment or for whom initiation of treatment has been prescribed, for one of its Swiss indications:  Microangiopathies, in particular diabetic retinopathy. Clinical symptoms of chronic venous insufficiency of the legs (pains, cramps, paraesthesia, oedemas, stasis dermatitis), superficial thrombophlebitis in adjuvant treatment. Haemorrhoidal syndrome, post-thrombotic syndrome, microcirculatory disorders of arteriovenous origin. Male or female Aged ≥18 years Subject has provided the appropriate written informed consent. Subject must provide written informed consent before any study-specific procedures are performed  Exclusion Criteria:  Known sensitivity to calcium dobesilate Currently suffering from or treated for a nasal condition, e.g., a runny, congested nose, nasal infection, or an oral condition, e.g., oral infection, including suspected SARS-CoV-2 infection Currently treated with a nasal or an oral product, or any treatment with the same active substance as in CaD (e.g., doxiproct, dicynone) Current participation in any other investigational drug study Only for patients already on CaD treatment: treatment with CaD initiated within last 7 days only Only for patients starting CaD treatment: treatment with CaD within last 30 days